{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/stock/rmd-stock-analysis/", "dataUrl": "https://clearank.com/stock/rmd-stock-analysis/data.json", "title": "ResMed (RMD) Stock Forecast & Price Target (2026)", "description": "ResMed Inc. (RMD) stock: Healthcare, Medical Instruments & Supplies. $33.1B market cap. AI rating, technicals, 2030 forecast and trade plans.", "headline": "ResMed Inc. (RMD)", "published": "2026-07-22T10:05:09+00:00", "modified": "2026-09-16T08:25:55.286+00:00", "generated": "2026-09-16T10:59:25.457Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.", "asset": { "ticker": "RMD", "name": "ResMed Inc.", "type": "Common Stock", "exchange": "NYSE", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "country": "United States", "website": "https://www.resmed.com" }, "quote": { "price": 229.44, "previousClose": 222.99, "change": 6.45, "changePercent": 2.89, "open": 226.36, "high": 234.33, "low": 225.12, "volume": 1640900, "averageVolume": 1209520, "marketCap": 33097249088, "fiftyTwoWeekHigh": 284.87, "fiftyTwoWeekLow": 180.27, "marketOpen": false, "asOf": "2026-09-16T08:25:55.000Z" }, "statistics": { "pe": 21.379673, "eps": 10.43, "dividendYield": 0.011505774831609668, "beta": 0.766, "priceToSales": 5.6897755, "priceToBook": 4.884134, "revenueTtm": 5653443072, "grossMargin": 0.5884062208988916, "returnOnEquity": 0.24269 }, "technicals": { "rsi": 40.78, "macd": 1.11, "sma50": 217.45, "sma200": 227.59, "rsiSignal": "Neutral", "trend": "Bearish", "pricePosition": "Bullish", "macdSignal": "Bullish", "rating": "Neutral" }, "analysis": { "rating": "Hold", "score": 59, "consensus": "Hold", "fairValue": 235, "analystTarget": 235, "analystCount": 19, "wallStreetConsensus": "Hold", "generatedAt": "2026-09-16T08:25:55.000Z", "priceAtAnalysis": 229.44, "volatility": { "daily": 2.04, "risk": "standard" } }, "tradePlan": { "bias": "Neutral", "conservativeEntry": 227.15, "aggressiveEntry": 229.44, "stopLoss": 211.25, "stopLossPercent": 7, "targets": [ 233.96, 238.5, 245.32 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 167.72, "base": 253, "upside90th": 381.65 }, { "year": 2028, "downside10th": 155.99, "base": 278.99, "upside90th": 498.97 }, { "year": 2029, "downside10th": 150.94, "base": 307.64, "upside90th": 627.01 }, { "year": 2030, "downside10th": 149.09, "base": 339.24, "upside90th": 771.92 }, { "year": 2031, "downside10th": 149.19, "base": 374.08, "upside90th": 937.94 }, { "year": 2032, "downside10th": 150.7, "base": 412.5, "upside90th": 1129.11 }, { "year": 2033, "downside10th": 153.29, "base": 454.86, "upside90th": 1349.69 }, { "year": 2034, "downside10th": 156.81, "base": 501.58, "upside90th": 1604.38 }, { "year": 2035, "downside10th": 161.14, "base": 553.09, "upside90th": 1898.44 }, { "year": 2036, "downside10th": 166.22, "base": 609.89, "upside90th": 2237.83 } ] }, "faqCount": 7, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "price", "title": "RMD Price Analysis" }, { "id": "market-metrics", "title": "Market Metrics", "facts": { "Open": "$226.36", "Day Range": "$225.12 to $234.33", "Prev Close": "$222.99", "Volume": "1.64M", "52-Week Range": "$180.27 to $284.87", "Market Cap": "$33.10B" } }, { "id": "peer-benchmarking", "title": "Peer Benchmarking", "text": [ "Sector Position Analysis Trading at a notable discount to sector peers (-33%), which may indicate undervaluation or specific company headwinds." ] }, { "id": "financials", "title": "RMD Financial Performance", "text": [ "Analysis: In the last 4 quarters, RMD beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news." ] }, { "id": "analysis", "title": "RMD Analysis", "text": [ "ResMed Inc. (RMD) is currently trading above its 50-day and 200-day moving averages ($217.45 and $227.59), with its price at $229.44 sitting above the 50-day SMA of $217.45 and the 200-day SMA of $227.59. The Relative Strength Index (RSI) is at 40.78, indicating neutral momentum, and the MACD is slightly positive at 1.11. Volume has been above average recently, suggesting increased investor interest. Key support levels are suggested by the 50-day SMA and the 200-day SMA, while resistance may be found near recent highs. The chart structure shows a stock that has recovered from a dip below its 200-day SMA earlier in the year and is now consolidating. The neutral RSI suggests neither an overbought nor oversold condition, implying that the stock could move in either direction based on catalysts or broader market sentiment.", "Insiders have sold a net total of $42 million in ResMed Inc. (RMD) stock, with no reported insider purchases, signaling a potential lack of confidence in near-term stock appreciation.", "Wall Street analysts predominantly hold a 'Hold' rating on ResMed Inc. (RMD), with 11 out of 19 analysts issuing this rating, suggesting a balanced but not strongly bullish outlook.", "Current quarter revenue growth is estimated at +4.00% year-over-year, with full-year projections around +3.00%, indicating steady but not explosive growth that may limit significant price catalysts.", "ResMed Inc. (RMD) demonstrates strong profitability with a net profit margin of 26.95% and a return on equity of 24.27%, significantly outperforming sector averages and providing a strong fundamental basis.", "ResMed Inc. (RMD) is expected to maintain its current trading range in the near term, with a median analyst price target of $235.00 suggesting limited upside from its current price of $229.44. The company's strong profitability and solid balance sheet provide a stable foundation, but the neutral technical momentum and significant insider selling temper immediate bullish expectations. The consensus rating of Hold reflects this balanced view, indicating that while the company is fundamentally sound, there are no strong catalysts to drive substantial price appreciation in the immediate future. Potential upside could be driven by stronger-than-expected revenue growth in upcoming quarters or positive developments in new product pipelines, which are not explicitly detailed. Conversely, continued insider selling or increased competition leading to slower revenue growth could pressure the stock lower, potentially testing support levels around its 50-day and 200-day moving averages. Investors should monitor upcoming earnings reports and any shifts in analyst sentiment for directional cues." ], "lists": { "ProTips": [ "Monitor insider transaction activity closely, as recent net selling of $42 million by insiders may indicate a lack of near-term conviction.", "The stock's neutral RSI suggests it is neither overbought nor oversold, implying that current price levels may be a consolidation phase before a potential move.", "Given the moderate revenue growth projections, consider the competition within the medical devices sector and ResMed's ability to maintain market share." ] }, "catalysts": [ { "type": "Bearish", "title": "Significant Insider Selling Activity", "text": "Insiders have sold a net total of $42 million in ResMed Inc. (RMD) stock, with no reported insider purchases, signaling a potential lack of confidence in near-term stock appreciation.", "source": "Insider Transactions" }, { "type": "Neutral", "title": "Majority of Analysts Rate Stock as Hold", "text": "Wall Street analysts predominantly hold a 'Hold' rating on ResMed Inc. (RMD), with 11 out of 19 analysts issuing this rating, suggesting a balanced but not strongly bullish outlook.", "source": "Wall Street Consensus" }, { "type": "Neutral", "title": "Moderate Revenue Growth Projections", "text": "Current quarter revenue growth is estimated at +4.00% year-over-year, with full-year projections around +3.00%, indicating steady but not explosive growth that may limit significant price catalysts.", "source": "Wall Street Revenue Estimates" }, { "type": "Bullish", "title": "Strong Profitability and ROE", "text": "ResMed Inc. (RMD) demonstrates strong profitability with a net profit margin of 26.95% and a return on equity of 24.27%, significantly outperforming sector averages and providing a strong fundamental basis.", "source": "Company Fundamentals" } ] }, { "id": "key-statistics", "title": "Key Statistics", "text": [ "ResMed Inc. (RMD) presents a mixed valuation picture, trading at a Price-to-Earnings (P/E) ratio of 21.38, which is below the sector median of 31.9, suggesting it may be relatively undervalued compared to its peers. Its Price-to-Sales (P/S) ratio stands at 5.69, also below the sector average of 3.7, indicating a premium valuation on sales. The company demonstrates strong profitability with a net profit margin of 26.95% and an operating margin of 30.86%, significantly outperforming the sector's median Return on Equity (ROE) of 6.9%. The company's debt-to-equity ratio is a healthy 0.13, well below the sector average of 0.13, indicating a strong balance sheet with minimal leverage. While the current valuation metrics on sales appear high relative to the sector, the company's superior profitability and growth potential, as evidenced by its strong ROE and projected revenue growth, provide a solid fundamental underpinning. The key challenge remains aligning this fundamental strength with current market sentiment and analyst price targets.", "ResMed Inc. (RMD) has consistently met or slightly exceeded analyst expectations in its recent quarterly earnings reports. For the quarter ending June 2026, the company reported an Earnings Per Share (EPS) of $2.95, surpassing the estimate of $2.89 by 2.08%, although this resulted in a price decrease of 5.06%. This pattern of slight beats has been consistent across the last four reported quarters, with price reactions varying from negative to slightly positive. Revenue growth for the current quarter is estimated at +4.00% year-over-year, with projections for the next quarter at +2.00%. Full-year revenue growth is anticipated to be around +3.00%. While earnings have been stable, the moderate revenue growth suggests a maturing market or increased competition, which may be contributing to the cautious analyst sentiment.", "A primary risk for ResMed Inc. (RMD) is the significant insider selling activity, with $42 million in sales and no reported purchases, indicating a potential lack of confidence from management regarding near-term stock performance. Also, the stock's neutral RSI and the majority of Wall Street analysts rating it as 'Hold' suggest limited near-term upside potential and a lack of strong conviction from the broader analyst community. Finally, while revenue growth is positive, it is moderate at around 4% for the current quarter, which could signal increasing competitive pressures or market saturation in its core business segments." ], "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "Market Cap", "cells": [ "33.10B" ] }, { "label": "P/E Ratio", "cells": [ "21.38" ] }, { "label": "EPS (TTM)", "cells": [ "10.43" ] }, { "label": "Dividend Yield", "cells": [ "1.07%" ] }, { "label": "52 Week High", "cells": [ "284.87" ] }, { "label": "52 Week Low", "cells": [ "180.27" ] } ] } ] }, { "id": "technical-indicators", "title": "Technical Indicators", "text": [ "Technical Rating Neutral RSI Neutral SMA Cross Bearish Price vs SMA Bullish MACD Bullish Moving averages show a lagging Death Cross (50-day: $217.45, 200-day: $227.59), price action is firmly bullish above key moving averages." ], "facts": { "RSI": "Neutral", "SMA Cross": "Bearish", "Price vs SMA": "Bullish", "MACD": "Bullish" }, "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "RSI (14)", "cells": [ "40.78" ] }, { "label": "MACD", "cells": [ "1.11" ] }, { "label": "SMA 50", "cells": [ "217.45" ] }, { "label": "SMA 200", "cells": [ "227.59" ] } ] } ] }, { "id": "correlations", "title": "Market Correlations", "text": [ "How this stock moves relative to other assets", "Based on 1 year of daily price data. Correlations may vary over different time periods." ], "facts": { "Correlation with S&P 500 (SPY)": "+0.33", "Correlation with Nasdaq 100 (QQQ)": "+0.22", "Correlation with Bitcoin (BTC)": "+0.25", "Correlation with Gold (XAU)": "+0.12" } }, { "id": "trade-plans", "title": "RMD Trade Plans", "text": [ "Specific entry, exit, and risk management levels", "Enter now if confident", "Volatility-Adjusted Stop Loss Calculated based on RSI (40.8) and current market volatility", "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3" ], "facts": { "TARGET 1": "$233.96", "TARGET 2": "$238.50", "TARGET 3": "$245.32", "STOP LOSS": "$211.25" } }, { "id": "seasonality", "title": "Seasonal Patterns", "text": [ "Historical monthly performance trends", "Based on 3 years of historical monthly returns" ], "facts": { "Average Jan return": "+2.58%", "Average Feb return": "-0.82%", "Average Mar return": "-1.37%", "Average Apr return": "+0.62%", "Average May return": "+1.15%", "Average Jun return": "+6.11%", "Average Jul return": "+6.10%", "Average Aug return": "-1.29%", "Average Sep return": "-2.27%", "Average Oct return": "+0.72%", "Average Nov return": "+3.10%", "Average Dec return": "+0.16%" } }, { "id": "risk", "title": "Risk & Volatility", "facts": { "Daily Volatility": "2.04%" }, "lists": { "Risk considerations": [ "Monitor position sizing based on current volatility levels", "Consider stop-loss placement beyond recent price range", "Diversification helps mitigate single-stock risk exposure" ] } }, { "id": "growth", "title": "Growth of $10,000", "text": [ "A $10,000 investment in RMD in September 2016 would be worth about $35,594 today, compared with about $35,497 for the same investment in the S&P 500 benchmark." ] }, { "id": "monte-carlo", "title": "Monte Carlo Projection (10yr)", "text": [ "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RMD today could grow to about $26,582 by 2036 in the base case, with a bull case near $97,534 and a bear case around $7,245. Projections are statistical simulations, not guarantees." ] }, { "id": "price-prediction", "title": "RMD Stock Price Prediction: 2030", "text": [ "CleaRank's simulation projects a price near $339 for RMD by 2030 in the base case, from $229 today (1.5x over 4 years). The downside path ends near $149. These are outcomes of a Monte Carlo simulation run on RMD's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: 10,000 simulated price paths using RMD's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice." ], "tables": [ { "caption": "RMD simulated price paths by year", "columns": [ "Year", "Downside (10th pct)", "Base case", "Upside (90th pct)" ], "rows": [ { "label": "2027", "cells": [ "$168", "$253", "$382" ] }, { "label": "2028", "cells": [ "$156", "$279", "$499" ] }, { "label": "2029", "cells": [ "$151", "$308", "$627" ] }, { "label": "2030", "cells": [ "$149", "$339", "$772" ] }, { "label": "2031", "cells": [ "$149", "$374", "$938" ] }, { "label": "2032", "cells": [ "$151", "$412", "$1,129" ] }, { "label": "2033", "cells": [ "$153", "$455", "$1,350" ] }, { "label": "2034", "cells": [ "$157", "$502", "$1,604" ] }, { "label": "2035", "cells": [ "$161", "$553", "$1,898" ] }, { "label": "2036", "cells": [ "$166", "$610", "$2,238" ] } ] } ] }, { "id": "people-also-watch", "title": "People Also Watch", "links": [ { "text": "LLY Eli Lilly and Company NYSE $1,146.56 +0.73%", "url": "https://clearank.com/stock/eli-lilly-lly/" }, { "text": "NTRA Natera, Inc. NASDAQ $350.78 +2.63%", "url": "https://clearank.com/stock/natera-ntra/" }, { "text": "LEGN Legend Biotech Corporation NASDAQ $17.67 -4.64%", "url": "https://clearank.com/stock/legend-biotech-legn/" }, { "text": "VKTX Viking Therapeutics, Inc. NASDAQ $31.53 -1.41%", "url": "https://clearank.com/stock/viking-therapeutics-vktx/" }, { "text": "AMGN Amgen Inc. NASDAQ $375.65 -1.53%", "url": "https://clearank.com/stock/amgen-amgn/" }, { "text": "TLRY Tilray Brands Inc. NASDAQ $3.99 -3.62%", "url": "https://clearank.com/stock/tilray-brands-tlry/" }, { "text": "BMY Bristol-Myers Squibb Company NYSE $63.73 -0.58%", "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/" }, { "text": "IONS Ionis Pharmaceuticals, Inc. NASDAQ $47.25 -8.15%", "url": "https://clearank.com/stock/ions-stock-analysis/" } ] }, { "id": "related-comparisons", "title": "Popular Comparisons", "links": [ { "text": "XLF vs XLK Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/xlf-vs-xlk/" }, { "text": "Copper Futures (HG1) vs Gold Spot (XAU/USD) Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/copper-vs-gold/" }, { "text": "VUG vs VGT Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/vug-vs-vgt/" } ] }, { "id": "insider-trading", "title": "RMD Insider Trading Analysis", "facts": { "Bought": "None", "Sold": "$42.0M", "Insiders": "15", "Avg Transaction": "$793.1K" }, "tables": [ { "caption": "Recent insider transactions in RMD", "columns": [ "Date", "Insider", "Type", "Shares", "Value" ], "rows": [ { "label": "Aug 5, 2024", "cells": [ "LEONG JUSTIN Officer", "Sell", "48.0K", "$10.4M" ] }, { "label": "Feb 22, 2024", "cells": [ "FARRELL PETER CRAIG Director", "Sell", "23.5K", "$5.0M" ] }, { "label": "Sep 15, 2022", "cells": [ "DOUGLAS ROBERT ANDREW President", "Sell", "17.2K", "$4.0M" ] }, { "label": "Sep 9, 2024", "cells": [ "FARRELL MICHAEL J Chief Executive Officer", "Sell", "14.7K", "$3.6M" ] }, { "label": "Nov 7, 2024", "cells": [ "FARRELL MICHAEL J Chief Executive Officer", "Sell", "14.7K", "$3.6M" ] }, { "label": "Oct 7, 2024", "cells": [ "FARRELL MICHAEL J Chief Executive Officer", "Sell", "14.7K", "$3.4M" ] }, { "label": "May 7, 2024", "cells": [ "FARRELL MICHAEL J Chief Executive Officer", "Sell", "14.7K", "$3.2M" ] }, { "label": "Aug 7, 2024", "cells": [ "FARRELL MICHAEL J Chief Executive Officer", "Sell", "14.7K", "$3.1M" ] }, { "label": "Jun 7, 2024", "cells": [ "FARRELL MICHAEL J Chief Executive Officer", "Sell", "14.7K", "$3.1M" ] }, { "label": "Aug 20, 2021", "cells": [ "SANDERCOCK BRETT A Chief Financial Officer", "Sell", "10.7K", "$3.0M" ] } ] } ], "links": [ { "text": "SEC Form 4", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=ResMed+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany" } ] }, { "id": "faq", "title": "Frequently Asked Questions" } ], "faq": [ { "question": "Is ResMed Inc. (RMD) stock a buy right now?", "answer": "ResMed Inc. (RMD) is currently rated as a Hold by Wall Street analysts, with a median price target of $235.00, implying a modest 2.4% upside from its current price of $229.44. While the company exhibits strong fundamentals and consistent earnings beats, significant insider selling and neutral technical momentum suggest caution." }, { "question": "What is RMD's stock price forecast for 2030?", "answer": "Based on Monte Carlo simulations, ResMed Inc.'s (RMD) stock price is projected to be $339.24 in 2030 under a base case scenario. The downside projection is $149.09, and the upside projection is $771.92. These figures represent simulation outcomes, not guaranteed price targets." }, { "question": "How does ResMed Inc. compare to its sector averages?", "answer": "ResMed Inc. (RMD) shows a P/E ratio of 21.38, which is lower than the Healthcare sector median of 31.9, but its P/S ratio of 5.69 is higher than the sector median of 3.7. The company's ROE of 24.27% significantly outperforms the sector median of 6.9%, indicating superior profitability." }, { "question": "What is the recent earnings performance of ResMed Inc.?", "answer": "ResMed Inc. (RMD) has consistently reported earnings slightly above analyst estimates in recent quarters. For the quarter ending June 2026, EPS was $2.95 against an estimate of $2.89, a 2.08% surprise, though the stock saw a 5.06% decline post-announcement." }, { "question": "What are the main risks facing ResMed Inc. stock?", "answer": "Key risks for ResMed Inc. (RMD) include significant insider selling totaling $42 million, a majority 'Hold' rating from Wall Street analysts, and moderate revenue growth projections. These factors suggest potential headwinds for the stock's performance." }, { "question": "What is the dividend yield for ResMed Inc.?", "answer": "ResMed Inc. (RMD) offers a dividend yield of approximately 1.07%, with a dividend rate of $2.46." }, { "question": "What are the growth prospects for ResMed Inc. over the next five years?", "answer": "ResMed Inc. (RMD) is projected to grow at a compound annual growth rate of approximately 12% over the next five years, according to Wall Street estimates. This growth is supported by strong fundamental metrics and consistent earnings performance." } ], "related": { "peopleAlsoWatch": [ { "ticker": "LLY", "name": "Eli Lilly and Company NYSE", "price": "$1,146.56", "change": "+0.73%", "url": "https://clearank.com/stock/eli-lilly-lly/" }, { "ticker": "NTRA", "name": "Natera, Inc. NASDAQ", "price": "$350.78", "change": "+2.63%", "url": "https://clearank.com/stock/natera-ntra/" }, { "ticker": "LEGN", "name": "Legend Biotech Corporation NASDAQ", "price": "$17.67", "change": "-4.64%", "url": "https://clearank.com/stock/legend-biotech-legn/" }, { "ticker": "VKTX", "name": "Viking Therapeutics, Inc. NASDAQ", "price": "$31.53", "change": "-1.41%", "url": "https://clearank.com/stock/viking-therapeutics-vktx/" }, { "ticker": "AMGN", "name": "Amgen Inc. NASDAQ", "price": "$375.65", "change": "-1.53%", "url": "https://clearank.com/stock/amgen-amgn/" }, { "ticker": "TLRY", "name": "Tilray Brands Inc. NASDAQ", "price": "$3.99", "change": "-3.62%", "url": "https://clearank.com/stock/tilray-brands-tlry/" }, { "ticker": "BMY", "name": "Bristol-Myers Squibb Company NYSE", "price": "$63.73", "change": "-0.58%", "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/" }, { "ticker": "IONS", "name": "Ionis Pharmaceuticals, Inc. NASDAQ", "price": "$47.25", "change": "-8.15%", "url": "https://clearank.com/stock/ions-stock-analysis/" } ], "comparisons": [ { "ticker": "XLF vs XLK Comparison", "name": "", "url": "https://clearank.com/compare/xlf-vs-xlk/" }, { "ticker": "Copper Futures (HG1) vs Gold Spot (XAU/USD) Comparison", "name": "", "url": "https://clearank.com/compare/copper-vs-gold/" }, { "ticker": "VUG vs VGT Comparison", "name": "", "url": "https://clearank.com/compare/vug-vs-vgt/" } ], "sectorHub": { "text": "Browse all Healthcare →", "url": "https://clearank.com/sector/healthcare/" }, "Newly Tracked": [ { "ticker": "ILMN", "text": "Illumina Inc.", "url": "https://clearank.com/stock/ilmn-stock-analysis/" }, { "ticker": "ROST", "text": "Ross Stores Inc.", "url": "https://clearank.com/stock/rost-stock-analysis/" }, { "ticker": "LUGDF", "text": "Lundin Gold Inc", "url": "https://clearank.com/stock/lugdf-stock-analysis/" }, { "ticker": "KEYS", "text": "Keysight Technologies, Inc.", "url": "https://clearank.com/stock/keys-stock-analysis/" }, { "ticker": "BRO", "text": "Brown & Brown Inc.", "url": "https://clearank.com/stock/bro-stock-analysis/" } ], "Top Movers (24h)": [ { "ticker": "FPS", "text": "↑ 9.50%", "url": "https://clearank.com/stock/fps-stock-analysis/" }, { "ticker": "QRVO", "text": "↑ 9.34%", "url": "https://clearank.com/stock/qorvo-qrvo/" }, { "ticker": "RAY/USD", "text": "↓ 9.20%", "url": "https://clearank.com/crypto/raydium-ray-usd/" }, { "ticker": "EGLD/USD", "text": "↓ 9.14%", "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/" }, { "ticker": "SBET", "text": "↓ 8.96%", "url": "https://clearank.com/stock/sharplink-sbet/" } ], "Also in Healthcare": [ { "ticker": "BDX", "text": "Becton, Dickinson and Company", "url": "https://clearank.com/stock/bdx-stock-analysis/" }, { "ticker": "ISRG", "text": "Intuitive Surgical", "url": "https://clearank.com/stock/intuitive-surgical-isrg/" }, { "ticker": "RGNX", "text": "REGENXBIO", "url": "https://clearank.com/stock/rgnx-stock-analysis/" }, { "ticker": "RXRX", "text": "Recursion", "url": "https://clearank.com/stock/rxrx-stock-analysis/" }, { "ticker": "WST", "text": "West", "url": "https://clearank.com/stock/wst-stock-analysis/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "alternateName": "CleaRank Financial AI", "url": "https://clearank.com", "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.", "slogan": "Clear data. Honest analysis.", "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "image": { "@id": "https://clearank.com/#logo" }, "sameAs": [ "https://x.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank", "https://t.me/clearank" ], "email": "info@clearank.com", "contactPoint": [ { "@type": "ContactPoint", "contactType": "customer support", "email": "info@clearank.com", "url": "https://clearank.com/contact/", "availableLanguage": "en" } ], "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "location": { "@id": "https://clearank.com/#place" }, "knowsAbout": [ "stock analysis", "ETF analysis", "cryptocurrency analysis", "forex trading", "trading simulation", "trade journaling", "position sizing", "risk management", "prop firm challenges", "online broker regulation" ], "publishingPrinciples": "https://clearank.com/editorial-code/", "ethicsPolicy": "https://clearank.com/editorial-code/", "ownershipFundingInfo": "https://clearank.com/about-us/", "owns": { "@id": "https://clearank.com/#app" }, "founder": { "@id": "https://clearank.com/writer/shaundavidb/#person" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/wp-content/uploads/2026/07/RMD-resmed-analysis-2026-07.png", "url": "https://clearank.com/wp-content/uploads/2026/07/RMD-resmed-analysis-2026-07.png", "width": "1280", "height": "720", "caption": "ResMed (RMD) stock price analysis chart for July 2026", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/stock/rmd-stock-analysis/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://clearank.com/stock/rmd-stock-analysis/", "name": "ResMed (RMD) Stock Price Analysis" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/stock/rmd-stock-analysis/#webpage", "url": "https://clearank.com/stock/rmd-stock-analysis/", "name": "ResMed (RMD) Stock Forecast & Price Target (2026)", "datePublished": "2026-07-22T10:05:09+00:00", "dateModified": "2026-09-16T08:25:55+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/wp-content/uploads/2026/07/RMD-resmed-analysis-2026-07.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/stock/rmd-stock-analysis/#breadcrumb" }, "reviewedBy": { "@id": "https://clearank.com/writer/shaundavidb/#person" } }, { "@type": "Person", "@id": "https://clearank.com/writer/shaundavidb/#person", "name": "Shaun David", "jobTitle": "Co-Founder", "url": "https://clearank.com/writer/shaundavidb/", "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg", "sameAs": [ "https://www.linkedin.com/in/shaun-david-697b5817a/" ], "worksFor": { "@id": "https://clearank.com/#organization" } }, { "@type": "Article", "@id": "https://clearank.com/stock/rmd-stock-analysis/#richSnippet", "headline": "ResMed (RMD) Stock Forecast & Price Target (2026)", "name": "ResMed (RMD) Stock Forecast & Price Target (2026)", "description": "ResMed Inc. (RMD) stock: Healthcare, Medical Instruments & Supplies. $33.1B market cap. AI rating, technicals, 2030 forecast and trade plans.", "datePublished": "2026-07-22T10:05:09+00:00", "dateModified": "2026-09-16T08:25:55+00:00", "author": { "@id": "https://clearank.com/#organization" }, "publisher": { "@id": "https://clearank.com/#organization" }, "publishingPrinciples": "https://clearank.com/editorial-code/", "about": { "@type": "Corporation", "name": "ResMed Inc.", "identifier": [ { "@type": "PropertyValue", "propertyID": "tickerSymbol", "value": "RMD" }, { "@type": "PropertyValue", "propertyID": "exchange", "value": "NYSE" } ], "description": "ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care. ResMed develops and markets cloud-connected medical devices, including positive airway pressure systems, masks, home ventilators, and related accessories used to", "tickerSymbol": "RMD", "sameAs": "https://www.resmed.com" }, "isPartOf": { "@id": "https://clearank.com/stock/rmd-stock-analysis/#webpage" }, "image": { "@id": "https://clearank.com/wp-content/uploads/2026/07/RMD-resmed-analysis-2026-07.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/stock/rmd-stock-analysis/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is ResMed Inc. (RMD) stock a buy right now?", "acceptedAnswer": { "@type": "Answer", "text": "ResMed Inc. (RMD) is currently rated as a Hold by Wall Street analysts, with a median price target of $235.00, implying a modest 2.4% upside from its current price of $229.44. While the company exhibits strong fundamentals and consistent earnings beats, significant insider selling and neutral technical momentum suggest caution." } }, { "@type": "Question", "name": "What is RMD's stock price forecast for 2030?", "acceptedAnswer": { "@type": "Answer", "text": "Based on Monte Carlo simulations, ResMed Inc.'s (RMD) stock price is projected to be $339.24 in 2030 under a base case scenario. The downside projection is $149.09, and the upside projection is $771.92. These figures represent simulation outcomes, not guaranteed price targets." } }, { "@type": "Question", "name": "How does ResMed Inc. compare to its sector averages?", "acceptedAnswer": { "@type": "Answer", "text": "ResMed Inc. (RMD) shows a P/E ratio of 21.38, which is lower than the Healthcare sector median of 31.9, but its P/S ratio of 5.69 is higher than the sector median of 3.7. The company's ROE of 24.27% significantly outperforms the sector median of 6.9%, indicating superior profitability." } }, { "@type": "Question", "name": "What is the recent earnings performance of ResMed Inc.?", "acceptedAnswer": { "@type": "Answer", "text": "ResMed Inc. (RMD) has consistently reported earnings slightly above analyst estimates in recent quarters. For the quarter ending June 2026, EPS was $2.95 against an estimate of $2.89, a 2.08% surprise, though the stock saw a 5.06% decline post-announcement." } }, { "@type": "Question", "name": "What are the main risks facing ResMed Inc. stock?", "acceptedAnswer": { "@type": "Answer", "text": "Key risks for ResMed Inc. (RMD) include significant insider selling totaling $42 million, a majority 'Hold' rating from Wall Street analysts, and moderate revenue growth projections. These factors suggest potential headwinds for the stock's performance." } }, { "@type": "Question", "name": "What is the dividend yield for ResMed Inc.?", "acceptedAnswer": { "@type": "Answer", "text": "ResMed Inc. (RMD) offers a dividend yield of approximately 1.07%, with a dividend rate of $2.46." } }, { "@type": "Question", "name": "What are the growth prospects for ResMed Inc. over the next five years?", "acceptedAnswer": { "@type": "Answer", "text": "ResMed Inc. (RMD) is projected to grow at a compound annual growth rate of approximately 12% over the next five years, according to Wall Street estimates. This growth is supported by strong fundamental metrics and consistent earnings performance." } } ] } ] }